Literature DB >> 9839001

Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H.

L X Shen1, E R Kandimalla, S Agrawal.   

Abstract

All phosphorothioate mixed-backbone oligonucleotides (MBOs) composed of deoxyribonucleotide and 2'-O-methylribonucleotide segments were studied for their target binding affinity, specificity, and RNase H activation properties. The 2'-O-methylribonucleotide segment, which does not activate RNase H, serves as a high affinity target-binding domain and the deoxyribonucleotide (DNA) segment, which binds to the target with a lower affinity than the former domain, serves as an RNase H-activation or target-cleaving domain. In order to understand the influence of the size and position of the DNA segment of MBOs on RNase H-mediated cleavage of the RNA target, we designed and synthesized a series of 18-mer MBOs with the DNA segment varying from a stretch of two to eight deoxyribonucleotides in the middle, at the 5'-end, or at the 3'-end, of the MBOs. UV absorbance melting experiments of the duplexes of the MBOs with the complementary and singly mismatched RNA targets suggest that the target binding affinity of the MBOs increases as the number of 2'-O-methylribonucleotides increases, and that the binding specificity is influenced by the size and position of the DNA segment. Analysis of RNase H assay results indicates that the minimum substrate cleavage site and cleavage efficiency of RNase H are influenced by the position of the DNA segment in the MBO sequence. RNA cleavage efficiency decreases as the position of the DNA segment of the MBO.RNA heteroduplex is changed from the 3'-end to the middle and to the 5'-end of the target strand. Studies with singly mismatched targets indicate that the RNase H-dependent point mutation selectivity of the MBOs is affected by both the position and size of the DNA segment in the MBO sequence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839001     DOI: 10.1016/s0968-0896(98)00131-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Molecular requirements for degradation of a modified sense RNA strand by Escherichia coli ribonuclease H1.

Authors:  Daniel R Yazbeck; Kyung-Lyum Min; Masad J Damha
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

2.  Repairing the Sickle Cell mutation. II. Effect of psoralen linker length on specificity of formation and yield of third strand-directed photoproducts with the mutant target sequence.

Authors:  Olga Amosova; Steven L Broitman; Jacques R Fresco
Journal:  Nucleic Acids Res       Date:  2003-08-15       Impact factor: 16.971

3.  Introduction and History of the Chemistry of Nucleic Acids Therapeutics.

Authors:  Michael J Gait; Sudhir Agrawal
Journal:  Methods Mol Biol       Date:  2022

4.  Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication.

Authors:  Joacim Elmén; Hong-Yan Zhang; Bartek Zuber; Karl Ljungberg; Britta Wahren; Claes Wahlestedt; Zicai Liang
Journal:  FEBS Lett       Date:  2004-12-17       Impact factor: 4.124

Review 5.  Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease.

Authors:  Isabel N Schellinger; Angelika R Dannert; Karin Mattern; Uwe Raaz; Philip S Tsao
Journal:  Front Cardiovasc Med       Date:  2021-04-15

6.  Evaluation of DNA segments in 2'-modified RNA sequences in designing efficient splice switching antisense oligonucleotides.

Authors:  Bao T Le; Sudhir Agarwal; Rakesh N Veedu
Journal:  RSC Adv       Date:  2021-04-13       Impact factor: 3.361

Review 7.  The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.

Authors:  Sudhir Agrawal
Journal:  Biomedicines       Date:  2021-05-03

Review 8.  The powerful world of antisense oligonucleotides: From bench to bedside.

Authors:  Anaïs M Quemener; Laura Bachelot; Anne Forestier; Emmanuelle Donnou-Fournet; David Gilot; Marie-Dominique Galibert
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-03-31       Impact factor: 9.349

9.  Hitting bacteria at the heart of the central dogma: sequence-specific inhibition.

Authors:  Louise Carøe Vohlander Rasmussen; Hans Uffe Sperling-Petersen; Kim Kusk Mortensen
Journal:  Microb Cell Fact       Date:  2007-08-10       Impact factor: 5.328

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.